Dr. Nordestgaard graduated as a medical doctor from University of Copenhagen in 1985. Scientific education included 2 years at Cornell University in Ithaca, New York, and 2 years St. Thomas’s Hospital in London, UK.

In 1990 he was awarded Doctor of Medical Sciences by University of Copenhagen and in 2016 Honorary Doctorate by University of Buenos Aires, Argentina.

Professor Nordestgaard has for more than 30 years continued his interest in the pathogenesis, diagnosis and treatment of hyperlipidemia, atherosclerosis, diabetes and cardiovascular disease, and has written extensively on these conditions.

In 1988-97 he acted as chairman of the Scandinavian Society for Atherosclerosis Research. In addition, in 1998-01 and in 2013-16 he was an Executive Committee member of the European Atherosclerosis Society and in 1999-02 an Executive Scientific Committee member of the European Society of Cardiology.

He is chairing the Copenhagen General Population Study and is also a steering committee member of the Copenhagen City Heart Study and of 4 large randomised intervention trials.

Professor Børge G Nordestgaard has supervised 63 Ph.D. students and 30 postdoctoral fellows, and has published 780 original articles and 120 reviews, book chapters, consensus statements, & editorials. His H-index is 124 in Web of Science and he is listed among the 6000 researchers World-wide with the most highly cited papers (n=83).

Dr. Nordestgaard makes the following disclosures:  Consultancies and talks sponsored by AstraZeneca, Sanofi, Regeneron, Akcea, Amgen, Kowa, Denka Seiken, Amarin, Novartis, Novo Nordisk, Esperion, and Silence Therapeutics.